Table 2

Disease characteristics and patient-reported outcomes of all patients with PsA at time of enrolment

All patientsPatients with PsA categorised by skin and joint activityP value
0%>0% to 3%>3%
LowM/HLowM/HLowM/H
Enthesitis, n
n (%) with SPARCC score >0
1542
282 (18.3)
258
22 (8.5)
109
23 (21.1)
447
61 (13.7)
227
79 (34.9)
256
18 (7.0)
245
79 (32.2)
<0.001
SPARCC score (among those with enthesitis)0.0003
 Mean (SD)4.1±3.12.9±2.15.3±3.13.0±2.34.4±2.83.9±2.54.8±3.8
 Median (IQR)3.0 (2.0, 6.0)2.0 (1.0, 4.0)6.0 (3.0, 7.0)2.0 (1.0, 4.0)4.0 (2.0, 7.0)3.5 (2.0, 6.0)4.0 (2.0, 7.0)
Dactylitis, n1542258109447227256245<0.001
 n (%) with dactylitis count >0141 (9.1)8 (3.1)10 (9.2)27 (6.0)39 (17.2)8 (3.1)49 (20.0)
Dactylitis count (among those with dactylitis)
 Mean (SD)2.2±1.81.4±0.72.4±1.81.6±1.32.4±2.01.1±0.42.7±1.80.018
 Median (IQR)2.0 (1.0, 3.0)1.0 (1.0, 1.5)1.5 (1.0, 4.0)1.0 (1.0, 2.0)2.0 (1.0, 3.0)1.0 (1.0, 1.0)2.0 (2.0, 4.0)
MDA, n1426245103416203238221<0.001
 n (%)639 (44.8)180 (73.5)22 (21.4)296 (71.2)33 (16.3)102 (42.9)6 (2.7)
Clinical global assessment of psoriasis, n1523255107440225255241
 Clear, n (% of N)380 (25.0)242 (94.9)95 (88.8)21 (4.8)14 (6.2)7 (2.8)1 (0.4)<0.001
 Almost clear, n (% of N)540 (35.5)13 (5.1)8 (7.5)298 (67.7)118 (52.4)61 (23.9)42 (17.4)<0.001
 Mild disease, n (% of N)372 (24.4)0 (0.0)4 (3.7)99 (22.5)76 (33.8)101 (39.6)92 (38.2)<0.001
 Moderate disease, n (% of N)200 (13.1)0 (0.0)0 (0.0)22 (5.0)17 (7.6)75 (29.4)86 (35.7)<0.001
 Severe disease, n (% of N)31 (2.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)11 (4.3)20 (8.3)<0.001
BSA (%), n1542258109447227256245<0.001
 Mean (SD)5.6±11.20.0±0.00.0±0.01.6±0.71.6±0.814.4±14.816.2±16.6
 Median (IQR)2.0 (1.0, 5.0)0.0 (0.0, 0.0)0.0 (0.0, 0.0)1.0 (1.0, 2.0)1.0 (1.0, 2.0)9.0 (6.0, 16.0)10.0 (5.0, 18.0)
CDAI, n1542258109447227256245<0.001
 Mean (SD)10.4±9.34.7±3.318.6±8.95.0±3.218.3±8.25.4±3.020.5±10.0
 Median (IQR)8.5 (3.5, 14.0)4.4 (1.7, 8.0)15.5 (12.0, 21.0)4.8 (2.0, 8.0)16.0 (12.5, 22.0)5.5 (3.0, 8.0)17.7 (13.5, 24.5)
DAS28-CRP, n85616573230122135131<0.001
 Mean (SD)2.6±1.11.8±0.63.5±0.92.0±0.63.7±0.92.0±0.63.9±0.9
 Median (IQR)2.4 (1.8, 3.3)1.8 (1.3, 2.3)3.4 (3.0, 4.1)2.0 (1.6, 2.5)3.5 (3.1, 4.1)2.0 (1.6, 2.4)3.8 (3.1, 4.4)
DAS28-CRP, n85616573230122135131<0.001
 Low, n (% of N)496 (57.9)156 (94.6)13 (17.8)193 (83.9)11 (9.0)117 (86.7)6 (4.6)<0.001
 Moderate, n (% of N)260 (30.4)9 (5.6)42 (57.5)37 (16.1)78 (63.9)18 (13.3)76 (58.0)<0.001
 High, n (% of N)100 (11.7)0 (0.0)18 (24.7)0 (0.0)22 (27.1)0 (0.00)49 (37.4)<0.001
Nail involvement, n (%)677 (43.9)66 (25.6)36 (33.0)174 (38.9)115 (50.7)127 (49.6)159 (64.9)<0.001
Nail PsO VAS (among those with nail involvement) (0–100): mean (SD)16.2±21.69.9±10.319.0±50.110.7±13.113.5±14.216.6±20.025.8±24.3<0.001
 Median (IQR)8.0 (4.0, 20.0)5.0 (3.0, 15.0)5.0 (3.0, 15.0)5.0 (3.0, 13.0)7.0 (4.0, 20.0)7.0 (4.0, 21.0)20.0 (5.0, 40.0)
HAQ (0–3), n1448248105420209241225<0.001
 Mean (SD)0.61±0.60.38±0.50.88±0.70.40±0.50.87±0.70.45±0.51.06±0.7
 Median (IQR)0.38 (0.0, 1.0)0.13 (0.0, 0.6)0.75 (0.3, 1.5)0.25 (0.0, 0.6)0.88 (0.4, 1.4)0.25 (0.0, 0.8)1.00 (0.5, 1.5)
Patient pain VAS (0–100), n1438247104418208239222<0.001
 Mean (SD)37.6±29.326.7±26.045.9±28.928.1±25.950.0±26.632.7±28.257.1±27.6
 Median (IQR)30.0 (10.0, 65.0)20.0 (5.0, 43.0)48.0 (17.5, 70.0)20.0 (5.0, 50.0)50.0 (30.0, 71.5)25.0 (10.0, 50.0)60.0 (35.0, 80.0)
EQ5D (0–1), n1516254105440225253239<0.001
 Mean (SD)72.3±21.179.4±18.964.3±23.877.9±17.566.5±20.776.9±16.958.8±23.4
 Median (IQR)80.0 (60.0, 90.0)85.0 (73.0, 92.0)70.0 (50.0, 80.0)80.0 (70.0, 90.0)70.0 (50.0, 81.0)80.0 (70.0, 90.0)60.0 (40.0, 80.0)
Patient-reported fatigue
(0–100), n
1517255107438223250244<0.001
 Mean (SD)40.2±29.131.4±27.245.2±29.433.3±27.149.7±27.837.4±29.154.0±28.2
 Median (IQR)40.0
(12.0, 65.0)
25.0
(8.0, 55.0)
45.0
(20.0, 70.0)
25.0
(10.0, 55.0)
50.0
(25.0, 75.0)
30.0
(10.0, 63.0)
60.0
(31.0, 75.0)
Morning stiffness, n1489251104429222241242<0.001
 0 hour, n (%)172 (11.6)46 (18.3)5 (4.8)67 (15.6)13 (5.9)32 (13.3)9 (3.7)
  • P value represents comparisons between CDAI/BSA subgroups and were analysed using χ2 tests, Fisher’s exact tests, t-tests or Wilcoxon-Mann-Whitney tests, as appropriate. Skin severity by levels of BSA: 0%, >0% to 3% and >3%; joint activity by levels of CDAI: low and M/H.

  • BSA, body surface area; CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28-joint count C-reactive protein; EQ5D, EuroQol Group 5-Dimensional Questionnaire; HAQ, Health Assessment Questionnaire; MDA, mild disease activity; M/H, moderate/high; PsA, psoriatic arthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; VAS, visual analogue scale.